However, the patient died due to hypoproteinemia combined with severe pneumonia in December 2023.<h4>Conclusion</h4>Furmonertinib may be effective for NSCLC patients with HER2 T8962A and L869R mutations and further studies are needed to confirm these results in prospective clinical trials. This evidence concerns the gene ERBB2 and susceptibility to pneumonia measurement.